Overview

Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients

Status:
Active, not recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
Sinonasal tumors are rare diseases, so no standard treatment for such aggressive tumors has been reported, given rarity, absence of prospective study and heterogeneity of histologies and stages of diseases. This study proposes innovative integration of multiple modality of treatment depending by histology, molecular profile and response to induction CT. Moreover, such strategies allows the use of latest technology with greater biological effectiveness and reduction of toxicities.
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Collaborator:
Regione Lombardia
Treatments:
Cisplatin
Docetaxel
Doxorubicin
Etoposide
Etoposide phosphate
Fluorouracil
Ifosfamide
Isophosphamide mustard
Leucovorin
Liposomal doxorubicin